Listening To Spravato™ Expands Clinical‑Music Research as Compass Pathways Advances COMP360

MONTCLAIR, N.J. - Sept. 26, 2026 - PRLog -- Montclair, NJ — Listening To LLC, developer of clinical‑music systems for SPRAVATO® treatment centers, announced an expansion of its research program to study Compass Pathways' investigational compound, COMP360. The company views COMP360 as a potential alternative or complement to SPRAVATO® (esketamine) and is preparing new clinical‑music protocols to support emerging dissociative therapies.

Listening To Spravato™ has established therapeutic sound standards used in thousands of SPRAVATO® sessions across the United States. As new compounds enter the field, the company is evaluating how differences in sensory profile, onset, and dissociative intensity may require distinct auditory environments to maintain patient safety.

"Each dissociative compound produces a unique sensory experience," said founder Justin Page. "Clinical music must be designed specifically for that profile. It cannot be swapped between treatments."

Listening To LLC is developing compound‑specific playlists, dissociation‑safe soundscapes, and treatment‑room acoustic guidelines to support both SPRAVATO® and future therapies such as COMP360. The company anticipates that treatment centers will increasingly require multi‑compound clinical‑music systems capable of maintaining stable, predictable sensory conditions.

About Listening To LLC
Listening To LLC creates clinical‑music products and services for SPRAVATO® treatment centers, including therapeutic playlists, sensory‑safe sound protocols, workflow integration, and treatment‑room acoustic standards. The company operates http://ListenSpravato.com, providing clinicians and patients with structured music resources that support safe dissociative experiences.